What Is Pemvidutide? Uses, Benefits, Safety, FDA Status, and Evidence

Medical review note: This article is for educational purposes only and does not provide medical advice. Pemvidutide is not FDA-approved. Products sold online as pemvidutide, ALT-801, GLP-1/glucagon peptides, or “research use only” pemvidutide may carry serious safety, quality, legal, and regulatory risks.

Quick answer

Pemvidutide is an investigational once-weekly dual glucagon-like peptide-1 and glucagon receptor agonist. It is being developed by Altimmune for metabolic dysfunction-associated steatohepatitis, called MASH, obesity, alcohol use disorder, and alcohol-associated liver disease. Pemvidutide is designed to combine GLP-1 receptor effects, such as appetite reduction and weight loss, with glucagon receptor effects, such as increased energy expenditure and liver-fat-related metabolic activity. It is not FDA-approved, but it has received FDA Fast Track designation for MASH and alcohol use disorder and FDA Breakthrough Therapy designation for MASH. Clinical trials show meaningful liver-fat reduction, weight loss, and MASH-resolution signals, but long-term cardiovascular outcomes, phase 3 results, and FDA approval remain unproven.

Key facts about Pemvidutide

What is pemvidutide?

Pemvidutide is an investigational dual GLP-1 and glucagon receptor agonist. It is a peptide-based drug candidate designed for metabolic and liver diseases.

Pemvidutide is being developed by Altimmune, a clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases.

Altimmune describes pemvidutide as a novel investigational peptide with balanced 1:1 glucagon and GLP-1 dual receptor agonist activity in development for MASH, obesity, alcohol use disorder, and alcohol-associated liver disease.

The key distinction:

Pemvidutide is not a finished consumer peptide. It is an investigational metabolic drug candidate in clinical development.

How does pemvidutide work?

Pemvidutide activates two receptor systems:

1. GLP-1 receptor
2. Glucagon receptor

The GLP-1 receptor side is associated with:

• Reduced appetite
• Increased satiety
• Slower gastric emptying
• Improved glucose-related metabolic signaling
• Weight loss support

The glucagon receptor side is associated with:

• Increased energy expenditure
• Effects on liver metabolism
• Liver-fat reduction
• Lipid and cardiometabolic effects
• Additional metabolic activity beyond GLP-1-only drugs

In plain English:

Pemvidutide is designed to reduce calorie intake through GLP-1 signaling while increasing energy expenditure and liver-fat metabolism through glucagon signaling.

That makes it different from GLP-1-only drugs.

The practical interpretation:

Pemvidutide sits in the GLP-1/glucagon dual-agonist category. It is especially interesting because of liver-fat, MASH, and body-weight effects.

What is pemvidutide used for?

Pemvidutide is being studied for liver and metabolic diseases. It is not approved for any use.

| Use | Evidence level | What is known | What is not known | |---|---|---| | MASH | Moderate phase 2 evidence | Phase 2b IMPACT data showed MASH-resolution benefit at 24 weeks and 48-week non-invasive fibrosis-marker improvements. | Phase 3 efficacy, final FDA approval, and long-term clinical outcomes remain unknown. | | MASLD / liver fat reduction | Moderate phase 2 evidence | Phase 2 data showed significant reductions in liver fat content, liver inflammation markers, and body weight. | Long-term liver outcomes and fibrosis-stage improvement need more evidence. | | Obesity / overweight | Moderate phase 2 evidence | Pemvidutide produces clinically meaningful weight loss in trials. | It is not FDA-approved for obesity, and long-term comparative results are still developing. | | Alcohol use disorder | Early clinical development | FDA granted Fast Track designation for AUD, and a phase 2 RECLAIM trial is underway. | Efficacy for AUD is not established. | | Alcohol-associated liver disease | Early clinical development | Altimmune initiated ALD research with RESTORE. | Clinical benefit is not established. | | Cardiometabolic markers | Early to moderate evidence | Trials report changes in body weight, liver fat, and metabolic markers. | Cardiovascular outcomes evidence is not established. | | Anti-aging / longevity | Unsupported | Weight and metabolic improvement may affect health risk. | Pemvidutide is not an anti-aging or longevity therapy. | | Bodybuilding / casual cutting | Unsupported and medically inappropriate | Appetite and weight effects may attract misuse. | It is not a bodybuilding drug. | | Online research-use pemvidutide | High risk | Sellers may market GLP-1/glucagon peptides online. | Quality, sterility, identity, dose, and legality may be unknown. |

What does the research show?

Phase 2b MASH evidence

Pemvidutide has phase 2b MASH evidence from the IMPACT trial.

A Lancet-published phase 2b study evaluated weekly pemvidutide versus placebo in biopsy-confirmed MASH. The PubMed abstract reports that pemvidutide met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks, but did not meet the fibrosis improvement endpoint at that time.

Altimmune later reported 48-week IMPACT data showing continued weight loss and improvements in non-invasive markers of fibrosis across treatment arms versus placebo.

The practical interpretation:

Pemvidutide has real MASH clinical signals, especially MASH resolution and metabolic improvement, but phase 3 confirmation is still required.

MASLD and liver-fat evidence

Pemvidutide has phase 2 evidence in metabolic dysfunction-associated steatotic liver disease, called MASLD.

A PubMed-indexed study reported that weekly pemvidutide treatment in patients with MASLD yielded significant reductions in liver fat content, markers of hepatic inflammation, and body weight compared with placebo.

A PMC-published study of 24 weeks of pemvidutide in MASLD reported significant reductions in liver fat content and body weight that further improved on 12-week results.

The practical interpretation:

Pemvidutide appears especially relevant to liver-fat reduction and liver-metabolism research, not just general weight loss.

Obesity and weight-loss evidence

Pemvidutide has shown meaningful weight-loss effects in clinical trials.

The dual GLP-1/glucagon mechanism is designed to combine appetite suppression with energy-expenditure effects. Altimmune states that GLP-1 suppresses appetite while glucagon increases energy expenditure.

The practical interpretation:

Pemvidutide has weight-loss potential, but it is not FDA-approved for obesity and should not be treated as interchangeable with approved obesity drugs such as Wegovy or Zepbound.

Alcohol use disorder and alcohol-associated liver disease

Pemvidutide is also being studied in alcohol-related indications.

Altimmune announced FDA Fast Track designation for pemvidutide in alcohol use disorder and initiated the RECLAIM phase 2 trial. Altimmune has also described pemvidutide development for alcohol-associated liver disease.

The practical interpretation:

Pemvidutide’s AUD and ALD research is early and interesting, but efficacy is not established.

FDA designations

Pemvidutide has important FDA development designations, but these are not approvals.

Altimmune announced FDA Fast Track designation for pemvidutide in MASH and AUD. Altimmune also announced FDA Breakthrough Therapy designation for pemvidutide in MASH after an end-of-phase 2 meeting with FDA.

The practical interpretation:

FDA Fast Track and Breakthrough Therapy designations suggest regulatory interest and potential unmet-need relevance. They do not mean pemvidutide is FDA-approved.

Evidence summary

Is pemvidutide FDA-approved?

No. Pemvidutide is not FDA-approved.

There is no FDA-approved pemvidutide product for MASH, MASLD, obesity, alcohol use disorder, alcohol-associated liver disease, weight loss, diabetes, anti-aging, or any other use.

Pemvidutide does have FDA development designations:

The blunt version:

Pemvidutide is promising, but not approved. FDA designation is not FDA approval.

Is pemvidutide legal?

Pemvidutide’s legal status depends on country, product type, prescription status, intended use, and whether it is part of a clinical trial.

For U.S. readers:

Pemvidutide is not FDA-approved, and online availability does not mean it is legally marketed for human therapeutic use.

The FDA has warned broadly about illegal or unverified GLP-1 drug ingredients entering the U.S. market. That concern applies especially to gray-market versions of investigational incretin drugs.

The blunt version:

Buying “research use only” pemvidutide online is not the same as receiving an approved metabolic medication from a legitimate pharmacy.

Is pemvidutide banned in sports?

Pemvidutide is a GLP-1/glucagon receptor dual agonist. Anti-doping status should be checked through official resources because rules can change and pemvidutide is investigational.

The USADA GLP-1 athlete guide says GLP-1 drugs are not currently prohibited in sport, but WADA is monitoring and evaluating GLP-1 agonist use by athletes.

Pemvidutide also activates the glucagon receptor, so athletes should not assume it is safe from an anti-doping perspective just because GLP-1 drugs are currently not prohibited.

The practical advice:

Athletes should verify pemvidutide through Global DRO, WADA, or USADA before use and should avoid unapproved online peptide products.

Safety and side effects

Pemvidutide has real pharmacologic activity. It should not be treated like a harmless supplement.

Common or likely side effects, based on trial data and incretin-drug class patterns, may include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite
• Abdominal discomfort
• Dyspepsia
• Dizziness
• Injection-site reactions
• Possible gallbladder-related issues
• Possible pancreatitis-related concerns by class analogy
• Possible dehydration risk from severe vomiting or diarrhea
• Possible hypoglycemia risk when combined with insulin or insulin secretagogues
• Unknown long-term cardiovascular outcomes
• Unknown long-term rare adverse-event profile outside trials

The glucagon receptor activity matters.

Glucagon receptor agonism may contribute to weight loss and liver-fat reduction, but it may also introduce different safety considerations than GLP-1-only drugs. Pemvidutide should not be casually described as “basically Ozempic.”

A serious evaluation of pemvidutide should separate:

Pemvidutide vs similar drugs and peptides

The key distinction:

Pemvidutide belongs in the GLP-1/glucagon dual-agonist category. It is not a GLP-1-only drug, not a GIP/GLP-1 drug, not an amylin analog, and not a generic peptide supplement.

Why is pemvidutide sold as “research use only”?

Some online sellers may use “research use only” language to sell pemvidutide or pemvidutide-like peptides outside normal prescription channels.

That label is not a trust signal.

A serious reader should understand this distinction:

How to evaluate pemvidutide claims online

Bottom line

Pemvidutide is an investigational once-weekly dual GLP-1 and glucagon receptor agonist being developed by Altimmune for MASH, obesity, alcohol use disorder, and alcohol-associated liver disease. Phase 2 evidence supports liver-fat reduction, weight loss, and MASH-resolution signals, and FDA has granted Fast Track and Breakthrough Therapy designations in specific contexts.

The most defensible conclusion is:

Pemvidutide is a serious investigational metabolic and liver-disease drug candidate, not a casual research peptide. It is not FDA-approved, phase 3 confirmation is still needed, and readers should distinguish monitored clinical-trial pemvidutide from unapproved online products with uncertain identity, purity, sterility, and legal status.

FAQ

What is pemvidutide?

Pemvidutide is an investigational once-weekly dual GLP-1 and glucagon receptor agonist developed by Altimmune. It is being studied for MASH, obesity, alcohol use disorder, and alcohol-associated liver disease.

What does pemvidutide do?

Pemvidutide activates GLP-1 receptors and glucagon receptors. It is designed to reduce appetite, support weight loss, influence energy expenditure, reduce liver fat, and improve metabolic and liver-related markers.

Is pemvidutide FDA-approved?

No. Pemvidutide is not FDA-approved for MASH, obesity, alcohol use disorder, alcohol-associated liver disease, or any other use.

Does pemvidutide have FDA Fast Track designation?

Yes. Pemvidutide has FDA Fast Track designation for MASH and alcohol use disorder.

Does pemvidutide have FDA Breakthrough Therapy designation?

Yes. Altimmune announced that pemvidutide received FDA Breakthrough Therapy designation for MASH.

Is pemvidutide the same as Ozempic?

No. Ozempic contains semaglutide, a GLP-1 receptor agonist. Pemvidutide is a dual GLP-1 and glucagon receptor agonist.

Is pemvidutide the same as Mounjaro?

No. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Pemvidutide targets GLP-1 and glucagon receptors.

Is pemvidutide the same as mazdutide?

No. Pemvidutide and mazdutide are both GLP-1/glucagon dual agonists, but they are different compounds developed by different companies. Mazdutide is approved in China; pemvidutide is not FDA-approved.

Does pemvidutide cause weight loss?

Clinical trials show that pemvidutide can produce meaningful weight loss. However, it is not FDA-approved as a weight-loss medication.

Does pemvidutide reduce liver fat?

Yes, phase 2 studies report significant reductions in liver fat content in MASLD and MASH-related research contexts.

Does pemvidutide treat MASH?

Pemvidutide has promising phase 2b MASH data and FDA Breakthrough Therapy designation for MASH, but it is not FDA-approved and phase 3 confirmation is still needed.

Does pemvidutide treat alcohol use disorder?

Pemvidutide is being studied for alcohol use disorder and has FDA Fast Track designation for AUD, but efficacy is not yet established.

Is pemvidutide safe?

Pemvidutide has clinical-trial safety data, but it is not risk-free. Common concerns include gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, abdominal discomfort, and appetite loss. Long-term outcomes and broader real-world safety data are still developing.

Is pemvidutide legal in the U.S.?

Pemvidutide is not FDA-approved in the U.S. Online sales as a research peptide do not mean it is legally marketed for human therapeutic use.

Is pemvidutide banned in sports?

GLP-1 drugs are not currently prohibited according to USADA guidance, but WADA is monitoring GLP-1 agonists. Because pemvidutide also activates glucagon receptors, athletes should verify current status through WADA, USADA, or Global DRO before use.

Why do sellers call pemvidutide “research use only”?

Sellers often use “research use only” language because pemvidutide is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically proven.

What is the biggest risk with pemvidutide?

The biggest risks are using an investigational metabolic drug without medical supervision, confusing FDA designations with approval, and buying online products with uncertain identity, purity, sterility, concentration, and safety.

Sources

1. Altimmune: Pemvidutide
2. Altimmune: FDA Fast Track Designation for Pemvidutide in MASH
3. Altimmune: FDA Breakthrough Therapy Designation for Pemvidutide in MASH
4. Lancet: Safety and efficacy of weekly pemvidutide versus placebo in MASH
5. PubMed: Safety and efficacy of weekly pemvidutide versus placebo in MASH
6. PMC: Safety and efficacy of 24 weeks of pemvidutide in MASLD
7. PubMed: Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, in MASLD
8. ScienceDirect: Effect of pemvidutide in MASLD
9. ClinicalTrials.gov: IMPACT Trial, Pemvidutide in NASH/MASH
10. Altimmune: RECLAIM Phase 2 Trial in Alcohol Use Disorder
11. Altimmune: 48-week IMPACT Phase 2b MASH Trial Update
12. FDA: Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
13. USADA: Weight Loss Drugs, What Athletes Need to Know About GLP-1s
14. WADA: GLP-1 Receptor Agonists Monitoring Research